Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
LAG-3
Pharma
ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop
Even though Opdualag failed in resected melanoma, BMS' Samit Hirawat said he’s not concerned about a more important study in metastatic lung cancer.
Angus Liu
Jun 3, 2025 8:00am
BMS’ Opdualag flunks trial as adjuvant for resected melanoma
Feb 14, 2025 8:15am
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
Bristol Myers’ top challenges, as seen by analysts
Jul 12, 2024 12:00pm
Regeneron's Libtayo delivers lung cancer win with BMS' Yervoy
Dec 1, 2022 12:25pm
ASCO: BMS offers closer look at Opdualag's LAG-3 melanoma win
May 26, 2022 5:00pm
